Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

That increase has boosted valuations, as the price-to-sales (P/S) ratio of 19 indicates that the stock is not cheap. Still, considering that ServiceNow's average P/S ratio over the last five years is ...

TANZANIA is set to host the 11th Asia-Africa Luminaries Conference, organised by the Merck Foundation, focusing on health ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

aDepartment of Hematology/Oncology, Comprehensive Cancer Center (CCC Munich), LMU University Hospital Munich, 81377 Munich, Germany bDepartment of Hematology, Oncology, and Cancer Immunology (CCM), ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Development methodologies combine old and new techniques, but getting any new material into high-volume manufacturing is a ...

A bounding pulse is when your heart beats strongly. You may feel your pulse in your neck, wrist, or foot. Here’s why it ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...